CN113755447A - 293A cell strain for producing adenovirus and preparation and application thereof - Google Patents

293A cell strain for producing adenovirus and preparation and application thereof Download PDF

Info

Publication number
CN113755447A
CN113755447A CN202111116064.4A CN202111116064A CN113755447A CN 113755447 A CN113755447 A CN 113755447A CN 202111116064 A CN202111116064 A CN 202111116064A CN 113755447 A CN113755447 A CN 113755447A
Authority
CN
China
Prior art keywords
cell
adenovirus
genome
seq
hygro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202111116064.4A
Other languages
Chinese (zh)
Other versions
CN113755447B (en
Inventor
施金秀
陈咏
罗燕
蒙伟能
蓝田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yunzhou Biosciences (guangzhou) Inc
Original Assignee
Yunzhou Biosciences (guangzhou) Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yunzhou Biosciences (guangzhou) Inc filed Critical Yunzhou Biosciences (guangzhou) Inc
Priority to CN202111116064.4A priority Critical patent/CN113755447B/en
Publication of CN113755447A publication Critical patent/CN113755447A/en
Application granted granted Critical
Publication of CN113755447B publication Critical patent/CN113755447B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0684Cells of the urinary tract or kidneys
    • C12N5/0686Kidney cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/02Cells for production
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10051Methods of production or purification of viral material
    • C12N2710/10052Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/30Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to the technical field of cell engineering, in particular to a 293A cell strain for producing adenovirus and preparation and application thereof. The cell is obtained by inserting an exogenous fragment containing LoxM2, HPRT intron and Hygro cassette into the position of Ad5 gene in 293A cell genome. The replicative adenovirus genome generated by the cell of the invention can not form complete adenovirus particles because the genome exceeds the packaging limit of the adenovirus particles, thereby solving the problems of RCA and HDEP pollution in the adenovirus production process.

Description

293A cell strain for producing adenovirus and preparation and application thereof
Technical Field
The invention relates to the technical field of cell engineering, in particular to a 293A cell strain for producing adenovirus and preparation and application thereof.
Background
Replication-defective adenoviruses have wide applications in gene medicine, vaccine preparation, oncolytic adenoviruses and the like.
Most of the replication-defective adenoviruses currently used are serotype 5 adenoviruses in which the E1 region and the E3 region are deleted. Since the E1 region is an essential region for adenovirus replication, replication-defective adenoviruses must proliferate in a complementing cell line containing the E1 region. The most widely used replication-defective adenovirus packaging cell is 293, which comprises sequences of 1-4344 bp in Ad5 genome, including inverted repeat sequence (ITR) at 5' end, packaging signal, E1a, E1b gene and pIX coding sequence. However, Replication-deficient adenoviruses overlap with the adenovirus genome fragment in 293 cells, and when homologous recombination occurs in the cells, the Replication-deficient adenoviruses can be converted into Replication-competent adenoviruses (RCA) by recovering the E1 region. The probability of RCA appearance gradually increases with the number of passages. RCA is a pollutant in the replication-defective adenovirus amplification process, and has potential safety problem when being used in human body, so RCA detection is necessary for replication-defective adenovirus virus medicine used in clinic.
The approach to solve this problem is mainly to construct and modify cell lines in two directions: (1) deletion regions are added when constructing adenoviral vectors, such as deletion of multiple regions essential for replication, e.g., region E2 and/or region E4. Replication-defective adenoviruses deleted for multiple fragments need to be recombined for multiple times to regain replication capacity, so that the occurrence probability of RCA is reduced and the capacity of a vector is increased, but with the increase of deletion regions, the difficulty in constructing a stable cell line for replication is increased, and the virus titer may be reduced with the increase of the deletion regions; (2) the cell line is modified, namely the Ad5 DNA sequence in the 293 cell line is deleted from the homologous region of the adenovirus vector, the homologous sequence is reduced as much as possible, and the RCA is reduced or eliminated, for example, the cell line PER.C6 widely applied to adenovirus packaging at present, although the effect of preventing the RCA is achieved by greatly reducing the homologous part between the cell genome and the adenovirus vector. However, 177bp homologous portions still exist in the vector used for matching with PER.C. 6 cells and PER.C. 6 cells, and helper-dependent E1-containing particles (HDEP) are generated by unconventional homologous recombination with a very low probability. HDEP contains the E1 region, and in the presence of an adenoviral vector or a wild-type adenovirus, a replication-competent recombinant adenovirus product may be produced, with potential risk.
Disclosure of Invention
The invention aims to overcome the defects of the prior art, provides a 293A cell strain for producing adenovirus and preparation and application thereof, and can solve the problems of RCA and HDEP pollution in the production process of adenovirus.
In order to achieve the purpose, the invention adopts the technical scheme that: a cell obtained by inserting an exogenous fragment comprising LoxM2, HPRT intron and Hygro cassette at the position of Ad5 gene (NCBI number: AY339865.1 of Ad5 virus) in the genome of 293A cells is provided. In the presence of Cre enzyme, LoxM2 can be inserted into other genes in a targeted manner, so that convenience is brought to further modification of cell strains. HPRT intron is an intron of the human gene, which can also be replaced by other suitable introns. Hygro cassette is used to provide a selection marker during cell construction.
The replicative adenovirus genome generated by the cell of the invention cannot form complete adenovirus particles because the genome exceeds the packaging limit of the adenovirus particles, thereby solving the problem of RCA and HDEP pollution in the adenovirus production process.
As a preferred embodiment of the cell of the present invention, the nucleotide sequence of LoxM2 is shown in SEQ ID NO.1, the nucleotide sequence of HPRT intron is shown in SEQ ID NO.2, and the nucleotide sequence of Hygro cassette is shown in SEQ ID NO. 3.
As a preferred embodiment of the cell of the present invention, the nucleotide sequence of the exogenous fragment is shown in SEQ ID NO. 5.
As a preferred embodiment of the cell of the present invention, the insertion site is 3522bp of Ad5 gene. This insertion site is chosen in the present invention because it is located at the intron of the Ad 5E 1B gene, and insertion of the foreign gene does not affect the normal expression of the gene, but if recombination occurs, the foreign fragment will be contained in the viral genome such that the genome exceeds the packaging limit and cannot form a complete particle.
The invention also provides a construction method of the cell, which is characterized in that an exogenous fragment containing LoxM2, HPRT intron and Hygro cassette is inserted into the position of the Ad5 gene in the 293A cell genome.
As a preferred embodiment of the construction method, the construction method is to use a non-homology-dependent targeted integration method to make the genome of 293A cells and plasmids carrying the exogenous fragments form DNA double-strand breaks by using a CRISPR/Cas9 system, and insert the linearized exogenous fragments into targeted sites of the cell genome by using a non-homology end-linked DNA repair pathway, so as to form targeted integration.
Non-homology dependent targeted integration (or HITI) dsb (double strand break) is formed by using CRISPR/Cas9 system for both genome and plasmid carrying exogenous fragment, and the linearized exogenous fragment is inserted into the targeted site of the cell genome by using DNA repair pathway of Non-homologous end joining (NHEJ) to form targeted integration. When the method mediates the site-specific insertion of the exogenous fragment into the cell genome, compared with the terminal-dependent homologous recombination HDR (the homologous-directed repair), the method can simultaneously edit the divided cell and the non-divided cell, has higher editing efficiency and lower insertion and deletion probability, and has wide application prospect. While most of the current methods for constructing such cell lines insert fragments into cells according to HDR homologous recombination, such targeted insertion methods are inefficient.
A293A cell strain which does not generate RCA and HDEP in the process of producing the replication-defective adenovirus vector is constructed by using the HITI method and is named as VB-293A. This cell line inserted an approximately 9Kb foreign fragment comprising LoxM2, HPRT intron and Hygro cassette at a position of 3522bp of the 293A Ad5 genome. When homologous recombination occurs, the genome of the generated replicative adenovirus cannot form a complete adenovirus particle because the genome exceeds the packaging limit of the adenovirus particle, so that the problem of RCA and HDEP pollution in the adenovirus production process is solved.
As a preferred embodiment of the construction method of the present invention, the plasmid carrying the exogenous fragment is pDOwn-HBV ployA-HPRT intron-mPGK-Hygro-SV40 pA-gRNA 2.
The invention provides a method for packaging adenovirus by using the cell, which is to infect the cell by adenovirus with deletion of E1 gene.
The invention also provides the application of the cell in preparing adenovirus.
The invention has the beneficial effects that:
the 293A cell strain for producing the non-RCA adenovirus is characterized in that an exogenous segment of about 9Kb is inserted into an intron region of E1b, and when a defective adenovirus vector is recombined in a cell, a genome exceeding the packaging limit of adenovirus particles is generated, so that the cell strain can be used for producing the adenovirus vector, the RCA and HDEP can be prevented from being generated, and the safety of the adenovirus vector is improved.
Drawings
FIG. 1: plasmid map of pDOwn-HBV ployA-HPRT intron-mPGK-Hygro-SV40 pA-gRNA 2.
FIG. 2: plasmid map of pRP [ CRISPR ] -EGFP/Puro-hCas9-U6> {293A/Ad-3522nt }.
FIG. 3: sequence map of the engineered 293A near the target site of insertion (including the insertion sequence).
FIG. 4: plasmid map of pAV [ Exp ] -CMV > EGFP.
Detailed Description
To more clearly illustrate the technical solutions of the present invention, the following embodiments are further described, but the present invention is not limited thereto, and these embodiments are only some examples of the present invention.
The sequence related by the invention is as follows:
SEQ ID NO. 1: the nucleotide sequence of LoxM 2;
SEQ ID NO. 2: an HPTR intron nucleotide sequence;
SEQ ID NO. 3: a hygro cassette nucleotide sequence;
SEQ ID NO. 4: a gRNA recognition sequence;
SEQ ID No. 5: exogenous fragments (the exogenous fragments are obtained by connecting 3 gene fragments in sequence and do not contain gRNA recognition sequences);
SEQ ID NO. 6: hCas9 nucleotide sequence;
SEQ ID NO. 7: a gRNA transcription cassette;
SEQ ID NO. 8: a Stuffer-LA-F (60) primer sequence;
SEQ ID NO. 9: a Stuffer-LA-R (60) primer sequence;
SEQ ID NO. 10: a Stuffer-RA-F (60) primer sequence;
SEQ ID NO. 11: a Stuffer-RA-R (60) primer sequence;
SEQ ID NO. 12: Hygro-F (60) primer sequence;
SEQ ID NO. 13: Hygro-R (60) primer sequence.
EXAMPLE 1 obtaining of exogenous fragments
Respectively synthesizing gene fragments LoxM2 (the nucleotide sequence is shown as SEQ ID NO. 1), HPRT intron (the nucleotide sequence is shown as SEQ ID NO. 2) and hygro cassette (the nucleotide sequence is shown as SEQ ID NO. 3), sequentially connecting the 3 gene fragments to obtain an exogenous fragment (the nucleotide sequence is shown as SEQ ID NO. 5), and respectively connecting gRNA recognition sequences (the nucleotide sequences are shown as SEQ ID NO. 4) to two ends of the exogenous fragment to obtain the exogenous fragment containing the gRNA recognition sequences.
EXAMPLE 2 construction of recombinant plasmid
(1) Construction of plasmid pDOwn-HBV ployA-HPRT intron-mPGK-Hygro-SV40 pA-gRNA2
The foreign fragment containing the recognition sequence of gRNA obtained in example 1 was cloned into the plasmid pDOwn-SapI-ccdB-Chl-SapI to obtain the recombinant plasmid pDOwn-HBV ployA-HPRT intron-mPGK-Hygro-SV40 pA-gRNA2, and the recombinant plasmid map is shown in FIG. 1.
(2) Construction of hCas9 and gRNA-carrying plasmid
Synthesizing a gene fragment hCas9 (nucleotide sequence is shown as SEQ ID NO. 6) and a gRNA transcription frame (nucleotide sequence is shown as SEQ ID NO. 7), cloning the gRNA sequence into a plasmid PX330-U6-BbsI-CBh-hSpCas9-CMV > EGFP/Puro to obtain a recombinant plasmid pRP [ CRISPR ] -EGFP/Puro-hCas9-U6> {293A/Ad-3522nt }, wherein the map of the recombinant plasmid is shown as figure 2.
EXAMPLE 3 construction of VB-293A cell line
By 3X 106And (3) paving 6 pore plates on each cell, and ensuring that the confluency of the cells reaches 80-90% every other day. The two plasmids constructed in example 2 were co-transfected into 293A cells (thermo Fisher Cat.: R70507) using Lipofect amine 3000 transfection reagent. According to the principle of NHEJ, hCas9/gRNA will simultaneously recognize and cleave the target site of the gene and the two target sites of plasmid pDOwn-HBV ployA-HPRT intron-mPGK-Hygro-SV40 pA-gRNA 2. The linearized exogenous fragment is inserted into a targeted site of the cell genome, thereby forming targeted integration. The total amount of plasmid transfected was 2.5. mu.g, plasmid pRP [ CRISPR ]]-EGFP/Puro-hCas9-U6>{293A/Ad-3522nt }: 1.7 mu g; plasmid pDOwn-HBV ployA-HPRT intron-mPGK-Hygro-SV40 pA-gRNA 2: 0.8 mu g; lipofectamine 3000: 7.5. mu.L. The liquid is changed every other day.
And (3) passaging the cells after 48 hours of transfection in a 6-well plate, changing the culture medium by using 150 mu g of Hygro +2.5 mu g of puro + 10% FBS + DMEM drug sieve every other day, carrying out drug sieve for 7 days, and enriching the positive cells by using a Hygro and Pure double drug sieve. After drug screening, extracting cell genome and carrying out PCR amplification by using three pairs of primers (Stuffer-LA-F (60)/Stuffer-LA-R (60), Stuffer-RA-F (60)/Stuffer-RA-R (60) and Hygro-F (60)/Hygro-R (60)), wherein the sequences of the three pairs of primers are shown in Table 1, and the three pairs of primers can be respectively amplified to obtain the partial sequences of the left arm, the right arm and the insert fragment of the integration site. The PCR product was sent to sequencing for validation of the insert sequence. And if the PCR results of the three pairs of primers are positive and the sequencing result is correct, the exogenous fragment is inserted into the target site.
After digesting the cells with the correct sequencing results from the six-well plate, the cells were diluted to 20cells/mL with a gradient of 150. mu.g Hygro + 10% FBS + DMEM, plated in 2 96-well plates at 100. mu.L per well, and the wells with only one cell were observed and labeled under a microscope. After 20 days, cells were plated on 12-well plates after they had grown to capacity in 96-well plates. After the cells grow over a 12-well plate, the cells are transferred to a 6-well plate, the cells are taken and respectively subjected to PCR amplification by using three pairs of primers (Stuffer-LA-F (60)/Stuffer-LA-R (60), Stuffer-RA-F (60)/Stuffer-RA-R (60), Hygro-F (60)/Hygro-R (60)), PCR amplification products are sent to sequencing, and whether a cell monoclonal target site is inserted into an exogenous sequence or not is preliminarily verified. And (3) respectively sequencing and comparing the partial sequences of the left arm, the right arm and the inserted fragment of the integration site by three pairs of primers, further amplifying and culturing the cell monoclonal with correct sequencing, extracting a genome group to test the inserted exogenous sequence and the nearby E1b gene, and confirming that the inserted fragment and the nearby sequence have no mutation. The obtained monoclonal cell line with correct sequencing was designated VB-293A, and the sequence map of the cell near the inserted target site is shown in FIG. 3.
TABLE 1 primer names and sequences
Primer name Sequence of
Stuffer-LA-F(60) GTGAGGCTACAGAGGAGGCTAGGAATCT
Stuffer-LA-R(60) AAGGGTCGTCCGCAGGATTCAG
Stuffer-RA-F(60) GTCTGGACCGATGGCTGTGTAGAAGT
Stuffer-RA-R(60) GAAATGGTGAGAGCCATCCACACAA
Hygro-F(60) CAAGACCTGCCTGAAACCGAACTG
Hygro-R(60) AAGCATCAGCTCATCGAGAGCCTG
TABLE 2 sequencing primer names and sequences
Primer name Sequence of
HPRT-F1 TTGATTCTTTGAATCTGGGTCACC
HPRT-F2 gccgaggtggagatagatacg
HPRT-F3 aaggtgctgaggtacgatgag
HPRT-F4 tctcttgttcatgtcctactgttc
HPRT intron-F1 tttaagggcaggaatcaccg
HPRT intron-F2 gattctcccacttcagcctccc
HPRT intron-F3 aagtaacttgcccaagattaccc
HPRT intron-R3 TCTTCTCTGCTGATCTGGTTGG
HPRT intron-F4 ccaaccagatcagcagagaa
HPRT intron-F5 tgcccattccagaagtttg
HPRT intro-F9 AGCAGTCCTTGTCACAGATGATG
HPRT intro-R1 GAAGTAAGTTGCCCACAGCCACAC
HPRT intro-R4 CACAGTTTTGGAGGCTGGGAA
HPRT intro-R4R-R AGCCTCTGAGCCCAGAAAGC
hygro-R2 CTCGGCCCAAAGCATCAGC
Stuffer-RA-R2(60) GCTTCCATCAAACGAGTTGGTGCT
Example 4 detection of the ability of VB-293A cells to Encapsulate
The detection of the virus-encapsulating capacity of the VB-293A cell comprises the following steps:
(1) after shaking overnight, the plasmid pAV [ Exp ] -CMV > EGFP (vector fruit der product No.: VB150925-10024) was extracted and the plasmid map was as shown in FIG. 4. The plasmid was digested with PacI and cut into two fragments: 2074bp, 33123bp, run glue to confirm complete digestion. The digested product was heated at 65 ℃ for 20min to inactivate the PacI enzyme.
(2) And (2) spreading a VB-293A monoclonal cell strain and a 293A cell strain (control) which are constructed in the example 3 on a 6-well plate respectively, and directly taking the enzyme-cutting inactivation product (containing Ad5 fragment) obtained in the step (1) to transfect the cells when the cells grow to 80% -90%. The DNA dose was 2.5. mu.g, and VB-293A and 293A cells were transfected with 7.5. mu.L of Lipofectamine 3000. The liquid is changed every other day, and the observation is continued for 10 days until the occurrence of comet-like spots. Liquid is changed after the comet-shaped spots appear until 90% of cells are diseased, and toxicity is collected. The cells and supernatant were collected and gently blown with a pipette to drop off the cells. Freeze-thaw was repeated three times at 37 deg.c/liquid nitrogen to lyse cells and release virus. Centrifuge at 2000g for 10min at 4 ℃. The virus-containing supernatants were aliquoted and frozen at-80 ℃.
(3) Recovering and expanding A549 cells, digesting the A549 cells, resuspending the A549 cells by using 10% FBS + DMEM, and diluting the A549 cells into 4 x 10 cells by using 270mL 10% FBS + DMEM after resuspension5cells/mL of cell suspension were plated in 12-well plates, 1mL per well, in a total of 21 plates in 12-well plates. The 12-well plate was placed in a 37 ℃ incubator overnight. Removing 12-well plate stock culture solution every other day, packaging and amplifying VB-293A monoclonal cell strain and 293A cell 3 × 1011VP adenovirus was diluted in 120mL 10% FBS + DMEM and added to 12 well plates at 1mL per well. Each sample was infected separately in 10 12 well plates. One 12-well plate was set up and 10% FBS + DMEM was added as a negative control. The 12-well plate was incubated in an incubator at 37 ℃ for 14 days. Fluid replacement was performed on day 7, adding 1mL 10% FBS + DMEM per well. After 14 days, the number of wells showing CPE (cytopathic effect) in 10 12-well plates packed with the amplified adenovirus using VB-293A monoclonal cell line and 293A cells, respectively, was observed, while the negative control well plate showed no CPE.
TABLE 3 detection of the cytotoxic potency of VB-293A cells
Figure BDA0003275372220000081
Figure BDA0003275372220000091
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
SEQUENCE LISTING
<110> Yun boat Biotechnology (Guangzhou) Ltd
<120> 293A cell strain for producing adenovirus and preparation and application thereof
<130> 2021.9.23
<160> 13
<170> PatentIn version 3.3
<210> 1
<211> 34
<212> DNA
<213> Artificial sequence
<400> 1
ataacttcgt ataagaaacc atatacgaag ttat 34
<210> 2
<211> 6325
<212> DNA
<213> Artificial sequence
<400> 2
ggaaaagagg actgcgtgtg ggaagagaag gtggaaatgg cgttttggtt gacatgtgcc 60
gcctgcgagc gtgctgcggg gaggggccga gggcagattc gggaatgatg gcgcggggtg 120
ggggcgtggg ggctttctcg ggagaggccc ttccctggaa gtttggggtg cgatggtgag 180
gttctcgggg cacctctgga ggggcctcgg cacggaaagc gaccacctgg gagggcgtgt 240
ggggaccagg ttttgccttt agttttgcac acactgtagt tcatctttat ggagatgctc 300
atggcctcat tgaagcccca ctacagctct ggtagcggta accatgcgta tttgacacac 360
gaaggaacta gggaaaaggc attaggtcat ttcaagccga aattcacatg tgctagaatc 420
cagattccat gctgaccgat gccccaggat atagaaaatg agaatctggt ccttaccttc 480
aagaacattc ttaaccgtaa tcagcctctg gtatcttagc tccaccctca ctggtttttt 540
cttgtttgtt gaaccggcca agctgctggc ctccctcctc aaccgttctg atcatgcttg 600
ctaaaatagt caaaaccccg gccagttaaa tatgctttag cctgctttat tatgattatt 660
tttgttgttt tggcaatgac ctggttacct gttgtttctc ccactaaaac tttttaaggg 720
caggaatcac cgccgtaact ctagcactta gcacagtact tggcttgtaa gaggtcctcg 780
atgatggttt gttgaatgaa tacattaaat aattaaccac ttgaacccta agaaagaagc 840
gattctattt catattaggc attgtaatga cttaaggtaa agagcagtgc tattaacgga 900
gtctaactgg gaatccagct tgtttgggct atttactagt tgtgtggctg tgggcaactt 960
acttcacctc tctgggctta agtcatttta tgtatatctg aggtgctggc tacctcttgg 1020
agttattgag aggattataa gacagtctat gtgaatcagc aacccttgca tggcccctgg 1080
cggggaacag taataatagc catcatcatg tttacttaca tagtcctaat tagtcttcaa 1140
aacagccctg tagcaatggt atgattatta ccattttaca gatgaggaac ctttgaagcc 1200
tcagagaggc taacagacat accctaggtc atacagttat taagagaagg agctctgtct 1260
cgaacctagc tctctctctc tcgagtaata ccagttaaaa aataggctac aaataggtac 1320
tcaaaaaaat ggtagtggct gttgttttta ttcagttgct gaggaaaaaa tgttgatttt 1380
tcatctctaa acatcaactt acttaattct gccaatttct tttttttgag acagggtctc 1440
actctgtcac ctaggatgga gtgcagtggc acaatcactg ctcactgcag cctcgacttc 1500
ccgggctcgg gtgattctcc ccaggctcag gggattctcc cacttcagcc tcccaagtag 1560
ctgggactac aggtgcgcac caccatccct ggctaatatt tgtactttat tttatttatt 1620
tatttattta ttttttgaga tggagtttcg ctcttgttgc ccgggctgga gtacagtggc 1680
atgatctcgg ctcagtgcaa cctctgcctc ccgggttcaa gcgattctcc tacctcatcc 1740
ccctgagtag ctgggattac aggcgcctgc caccatgcct ggctaatttt ttgtattttt 1800
aatagagacg aggtttcacc atgttggcca ggctactctc gaactcctga tctcaggtga 1860
tccacccgcc ttggcctccc aaagtgctgg gattacaggc gtgagccact gcgcccggcc 1920
taatatttgt attttttgta gagatggtgt tttgccatgt tgtccaggct ggtcttgaac 1980
tcctgagctc aagcgatctg cccgcctctg cttcccaaag tgctgggatt acaggcatga 2040
gccaccgtgc ctggcctagg tagacgcttt tagctttggg gtgtgatgcc tgccccagta 2100
tatagtgaat ttaattattg ctagagctgg ctgtttgtta gttttctttg aacataagat 2160
actcattgtt tttagtttgc aaatccctct tcctttttaa aaaatttctt tcccttaaat 2220
tgtttgcatg ttagcaataa caaatgctta aatggtgcta tgtgctagat actcttctaa 2280
gccctgttat gtatattaac taatttttta aattacacaa atcagagagg ttaagtaact 2340
tgcccaagat tacccaacaa tactaggatt tgaacctaag tttgtctcac cccagattct 2400
gctcttaatc tctaaacttt taagttagta gtgacaatag taggtattta ttgaatactt 2460
aactatgttt taggcgttga agtaaatatt ttgcaggcat tatctaatgt aaacacccta 2520
aagttacata acaggtaccc tttaggtaaa taaacactag tatgaccttg gaggcacaga 2580
tagttgaagt aacttgccca atatcactta catgaaattg gccctcaaat gtgtctgata 2640
caacccatgc tgcttgtaac tatcgtttta aactgccagg gtaaacttgg acacacttga 2700
gctaagaaaa agcttttaga tttttgcaaa ttaatgtgaa agatatgctt tatgtggata 2760
taatatcttc taaatttcgg ggatggtagt cctagaaatg taatcctgcc ctagccgagc 2820
ttaccctgcc aataattttt tacagaattg gtaaaacgga gcaccttttt tttgtccttg 2880
gccacactgt tatcaacagg gtgtagattg acatcaatct gtaggtgtaa accagaatta 2940
ctctttgtga ccaccaggaa atagagcagt tcagttcagg ggtttctttc tgtgaattta 3000
gcactgtgac ctgcatacta caagtctact ttgttttcta tccattgttt gtatctgggt 3060
attgcaaaag gtaggaaaag gaccaaccag atcagcagag aagagttgcc ttggagtttt 3120
cttttagttt tctgcagttc attagatagt aactaggcca tgtcatttta ctcccttgta 3180
gtgaagatat gttgaagttg tactggtata ctcttctacc tttctgtaat tttatattgt 3240
gtagacttga taaaatttat gtgtcaatca ccaccattaa tatcaatatt gagcctcaat 3300
tcttattttt ctgcccagtg gctgccaaat tactaacatt tacaataatt cactactact 3360
aagataatct actagttcga tcacatactt caaattgtta tggaactact gtcttcagca 3420
ttgtgcttct gataactgat aagtataatt ttttttttgt ccagagtgaa catgtctatt 3480
cttccactgt acacactaat aaaaggaaaa attgtaatat tgggtaaatt catgtcctta 3540
cacatgtagt agttatgagc ccatgtccct agaatgagta ataatttatc cctcccttgg 3600
ttgaatagtc aagaatgctg attttaattc ttctaacagc tttatccctc agaagggaag 3660
gcaagcaagt tatatatgta gtttatttgt aagactgata tgaaattgga agatgaatct 3720
actattagct ttaattattt ttacatttag gaatattgca tcagtaactc ataattttgg 3780
ttttctgtta tcctgagtta acacaaatta tccaaggaga tggcggatca tctgctttga 3840
ggtgtttttt tttgagaatt ttaatgtatc tgaatataaa aggtaaaaat atgccaacta 3900
gcaatttctg cccattccag aagtttggaa atattactca ttactaggaa ttaaataaaa 3960
tatggtttat ctattgttat acctctttta attcacatag ctcattttta tcttttattt 4020
ttgtttgttt tttttgagat ggagtcttgc tctgtcacca ggcaggagtg cagtgatgca 4080
atctcggctc actctagcca ccgactccct ggttcaagcg attctcctgc ctgagccttc 4140
tgagtagctg ggattacagg caggcaccac cacgcccagc taatttttgt agagacagga 4200
tttcaccgtg ttggccagga tggtctccat ctcctgacct catgatctgc ctgcttcggc 4260
ctcccaaagt gctgggatta caggtgggag ccactacgcc tggcccacat agctcatttt 4320
tagactcact tccattaagt cttgtttgga cccacgaaca ttgtcttttt ttttttaaga 4380
tggagtttca cttttgttgc ccagactgta gtgcaatggt gcaatctcag ctcactgcaa 4440
tctctgcctc ctgggttcta gcaattctcc tgcctcagcc tcccgagtag ctggaattac 4500
aggcgcccgc caccacgccc agctaatttt tgtgttttta gtagagacgg ggtttcacca 4560
tgttgggcag gccaggggtg atccgcccac ctcagcctcc caaagtgctg ggattacagg 4620
tgtgagccac cgcatctggc caacatgtct tttttttttt tttccttttt aaccacaaag 4680
agacttaagc agtccttgtc acagatgatg aattgatgtt gcaagtattg tcttagcttg 4740
gattaatttt cttgcttact gtaattttag ataatatagc tttgtaatta gagattttat 4800
gtgtaaacca caaaaatgtt tacatgaagg ccattattac agatgtgacg tgcataatta 4860
ttagtaattt gtatgtttac atgggtcagt ctggcaaaaa attatgaagt tttaaaaatt 4920
aaaaaaaatt ataatgccag ttttactgga aagtaaaatt atttcagtaa tcgattatag 4980
caaaagtatt gattttcatt ccagacaaaa gtcagaatga aaggtaattt ctcaatactc 5040
tttcagatta ataaaagtac ctgtagcgat ttttatcatt cacaagtata tcacaagtaa 5100
gttagaattt gagaactgtg ttctagatct ctgaggagat gcagtcagat ttctgaactg 5160
tctcagcaaa tggtaagtaa cttagagcta gtaattaata acctgtcctt tgatttctga 5220
ttcagccaag aatggccata tttgggaaag gcagatctgg agagtaacca cgttttcatt 5280
catttaccac ttctaggccc ctccagagct ctcagatatt ttggggttga gcccttcccc 5340
aaagccatac aggacctttt ttttgtgatc tgttctagcc atttttatgt tgggtgcttg 5400
ttatggactg agcatttatg tcctcccaca ccccccccat accttttttg aagtcctaac 5460
ccccagtgtg atggtatttg gagacagggc ctttggaagg taattacagt tagaagaagt 5520
cgggagggtt gggcccaggt ctgattggat tagtgccctt atatgaaaag acaccaggac 5580
gggcgcagtg gctcacacct gtaatcccag cactttggga ggccaaggtg ggtggatcac 5640
gaggtcagga gtttgagacc agcctggcca atgtagtgaa acaccatctc tactaaaaat 5700
acaaaaatta gctgggtgtg gtagcgggct cctgtcatcc aagctactcg ggagggtgag 5760
gcatgagaat cacttgaacc cgggagttgg aggttgcagt gagcccagat tgtgccactg 5820
tactccagcc tgggtgacag agtgagactc tgtctcaaaa aagaaaaaaa aaaaaaaaga 5880
gacaccagag agcttgttag aagaggtcat gtgagcacac agttagaaga ccttcaagcc 5940
aaagaagagg cctgagattg aaacctacct tgcaggtacc ttaattttgg acttcccagc 6000
ctccaaaact gtgagaaata agtttctgtt aagtcactca gtctgtggta ttttgttatg 6060
gcagcctgag caggtagttg ttctttcaga aggtgttgat aataaccaca tgcaacacca 6120
agtcacaaat aataaaacag atgtaactta tattcataca gaaagttggg cactgccatt 6180
gccttgttgg tttacacggc tgtgctagtt cagtagcaga aaggtgctgg tctcctttac 6240
tcagtttaca atctaggcag tagaatgtaa tcactgcttt aaacttgata ctgcttaggg 6300
agagaatcat tggtgctggg taact 6325
<210> 3
<211> 1771
<212> DNA
<213> Artificial sequence
<400> 3
ttctaccggg taggggaggc gcttttccca aggcagtctg gagcatgcgc tttagcagcc 60
ccgctgggca cttggcgcta cacaagtggc ctctggcctc gcacacattc cacatccacc 120
ggtaggcgcc aaccggctcc gttctttggt ggccccttcg cgccaccttc tactcctccc 180
ctagtcagga agttcccccc cgccccgcag ctcgcgtcgt gcaggacgtg acaaatggaa 240
gtagcacgtc tcactagtct cgtgcagatg gacagcaccg ctgagcaatg gaagcgggta 300
ggcctttggg gcagcggcca atagcagctt tgctccttcg ctttctgggc tcagaggctg 360
ggaaggggtg ggtccggggg cgggctcagg ggcgggctca ggggcggggc gggcgcccga 420
aggtcctccg gaggcccggc attctgcacg cttcaaaagc gcacgtctgc cgcgctgttc 480
tcctcttcct catctccggg cctttcgacc tcacgtggcc accatgaaaa agcctgaact 540
caccgcgacg tctgtcgaga agtttctgat cgaaaagttc gacagcgtct ccgacctgat 600
gcagctctcg gagggcgaag aatctcgtgc tttcagcttc gatgtaggag ggcgtggata 660
tgtcctgcgg gtaaatagct gcgccgatgg tttctacaaa gatcgttatg tttatcggca 720
ctttgcatcg gccgcgctcc cgattccgga agtgcttgac attggggaat ttagcgagag 780
cctgacctat tgcatctccc gccgtgcaca gggtgtcacg ttgcaagacc tgcctgaaac 840
cgaactgccc gctgttctgc agccggtcgc ggaggccatg gatgcgatcg ctgcggccga 900
tcttagccag acgagcgggt tcggcccatt cggaccgcaa ggaatcggtc aatacactac 960
atggcgtgat ttcatatgcg cgattgctga tccccatgtg tatcactggc aaactgtgat 1020
ggacgacacc gtcagtgcgt ccgtcgcgca ggctctcgat gagctgatgc tttgggccga 1080
ggactgcccc gaagtccggc acctcgtgca cgcggatttc ggctccaaca atgtcctgac 1140
ggacaatggc cgcataacag cggtcattga ctggagcgag gcgatgttcg gggattccca 1200
atacgaggtc gccaacatct tcttctggag gccgtggttg gcttgtatgg agcagcagac 1260
gcgctacttc gagcggaggc atccggagct tgcaggatcg ccgcggctcc gggcgtatat 1320
gctccgcatt ggtcttgacc aactctatca gagcttggtt gacggcaatt tcgatgatgc 1380
agcttgggcg cagggtcgat gcgacgcaat cgtccgatcc ggagccggga ctgtcgggcg 1440
tacacaaatc gcccgcagaa gcgcggccgt ctggaccgat ggctgtgtag aagtactcgc 1500
cgatagtgga aaccgacgcc ccagcactcg tccgagggca aaggaatagc agacatgata 1560
agatacattg atgagtttgg acaaaccaca actagaatgc agtgaaaaaa atgctttatt 1620
tgtgaaattt gtgatgctat tgctttattt gtaaccatta taagctgcaa taaacaagtt 1680
aacaacaaca attgcattca ttttatgttt caggttcagg gggaggtgtg ggaggttttt 1740
taaagcaagt aaaacctcta caaatgtggt a 1771
<210> 4
<211> 21
<212> DNA
<213> Artificial sequence
<400> 4
cacacatttc agtacctcaa t 21
<210> 5
<211> 8794
<212> DNA
<213> Artificial sequence
<400> 5
catttcagta cctcaataaa cataacttcg tataagaaac catatacgaa gttattgcgc 60
gggacgtcct ttgtttacgt cccgtcggcg ctgaatcctg cggacgaccc ttctcggggt 120
cgcttgggac tctctcgtcc ccttctccgt ctgccgttcc gaccgaccac ggggcgcacc 180
tctctttacg cggactcccc gtctgtgcct tctcatctgc cggaccgtgt gcacttcgct 240
tcacctctgc acgtcgcatg gagaccaccg tgaacgccca ccaaatattg cccaaggtct 300
tacataagag gactcttgga ctctcagcaa tgtcaacgac cgaccttgag gcatacttca 360
aagactgttt gtttaaagac tgggaggagt tgggggagga gattaggtta aaggtctttg 420
tactaggagg ctgtaggcat aaattggtct gcgcaccagc accatgcaac tttttcacct 480
ctgcctaatc atctcttgtt catgtcctac tgttcaagcc tccaagctgt gccttgggtg 540
gctttggggc atggacatcg acccttataa agaatttgga gctactgtgg agttactctc 600
gtttttgcct tctgacttct ttccttcagt acgagatctt caagtttgta caaaaaagca 660
ggctggaaaa gaggactgcg tgtgggaaga gaaggtggaa atggcgtttt ggttgacatg 720
tgccgcctgc gagcgtgctg cggggagggg ccgagggcag attcgggaat gatggcgcgg 780
ggtgggggcg tgggggcttt ctcgggagag gcccttccct ggaagtttgg ggtgcgatgg 840
tgaggttctc ggggcacctc tggaggggcc tcggcacgga aagcgaccac ctgggagggc 900
gtgtggggac caggttttgc ctttagtttt gcacacactg tagttcatct ttatggagat 960
gctcatggcc tcattgaagc cccactacag ctctggtagc ggtaaccatg cgtatttgac 1020
acacgaagga actagggaaa aggcattagg tcatttcaag ccgaaattca catgtgctag 1080
aatccagatt ccatgctgac cgatgcccca ggatatagaa aatgagaatc tggtccttac 1140
cttcaagaac attcttaacc gtaatcagcc tctggtatct tagctccacc ctcactggtt 1200
ttttcttgtt tgttgaaccg gccaagctgc tggcctccct cctcaaccgt tctgatcatg 1260
cttgctaaaa tagtcaaaac cccggccagt taaatatgct ttagcctgct ttattatgat 1320
tatttttgtt gttttggcaa tgacctggtt acctgttgtt tctcccacta aaacttttta 1380
agggcaggaa tcaccgccgt aactctagca cttagcacag tacttggctt gtaagaggtc 1440
ctcgatgatg gtttgttgaa tgaatacatt aaataattaa ccacttgaac cctaagaaag 1500
aagcgattct atttcatatt aggcattgta atgacttaag gtaaagagca gtgctattaa 1560
cggagtctaa ctgggaatcc agcttgtttg ggctatttac tagttgtgtg gctgtgggca 1620
acttacttca cctctctggg cttaagtcat tttatgtata tctgaggtgc tggctacctc 1680
ttggagttat tgagaggatt ataagacagt ctatgtgaat cagcaaccct tgcatggccc 1740
ctggcgggga acagtaataa tagccatcat catgtttact tacatagtcc taattagtct 1800
tcaaaacagc cctgtagcaa tggtatgatt attaccattt tacagatgag gaacctttga 1860
agcctcagag aggctaacag acatacccta ggtcatacag ttattaagag aaggagctct 1920
gtctcgaacc tagctctctc tctctcgagt aataccagtt aaaaaatagg ctacaaatag 1980
gtactcaaaa aaatggtagt ggctgttgtt tttattcagt tgctgaggaa aaaatgttga 2040
tttttcatct ctaaacatca acttacttaa ttctgccaat ttcttttttt tgagacaggg 2100
tctcactctg tcacctagga tggagtgcag tggcacaatc actgctcact gcagcctcga 2160
cttcccgggc tcgggtgatt ctccccaggc tcaggggatt ctcccacttc agcctcccaa 2220
gtagctggga ctacaggtgc gcaccaccat ccctggctaa tatttgtact ttattttatt 2280
tatttattta tttatttttt gagatggagt ttcgctcttg ttgcccgggc tggagtacag 2340
tggcatgatc tcggctcagt gcaacctctg cctcccgggt tcaagcgatt ctcctacctc 2400
atccccctga gtagctggga ttacaggcgc ctgccaccat gcctggctaa ttttttgtat 2460
ttttaataga gacgaggttt caccatgttg gccaggctac tctcgaactc ctgatctcag 2520
gtgatccacc cgccttggcc tcccaaagtg ctgggattac aggcgtgagc cactgcgccc 2580
ggcctaatat ttgtattttt tgtagagatg gtgttttgcc atgttgtcca ggctggtctt 2640
gaactcctga gctcaagcga tctgcccgcc tctgcttccc aaagtgctgg gattacaggc 2700
atgagccacc gtgcctggcc taggtagacg cttttagctt tggggtgtga tgcctgcccc 2760
agtatatagt gaatttaatt attgctagag ctggctgttt gttagttttc tttgaacata 2820
agatactcat tgtttttagt ttgcaaatcc ctcttccttt ttaaaaaatt tctttccctt 2880
aaattgtttg catgttagca ataacaaatg cttaaatggt gctatgtgct agatactctt 2940
ctaagccctg ttatgtatat taactaattt tttaaattac acaaatcaga gaggttaagt 3000
aacttgccca agattaccca acaatactag gatttgaacc taagtttgtc tcaccccaga 3060
ttctgctctt aatctctaaa cttttaagtt agtagtgaca atagtaggta tttattgaat 3120
acttaactat gttttaggcg ttgaagtaaa tattttgcag gcattatcta atgtaaacac 3180
cctaaagtta cataacaggt accctttagg taaataaaca ctagtatgac cttggaggca 3240
cagatagttg aagtaacttg cccaatatca cttacatgaa attggccctc aaatgtgtct 3300
gatacaaccc atgctgcttg taactatcgt tttaaactgc cagggtaaac ttggacacac 3360
ttgagctaag aaaaagcttt tagatttttg caaattaatg tgaaagatat gctttatgtg 3420
gatataatat cttctaaatt tcggggatgg tagtcctaga aatgtaatcc tgccctagcc 3480
gagcttaccc tgccaataat tttttacaga attggtaaaa cggagcacct tttttttgtc 3540
cttggccaca ctgttatcaa cagggtgtag attgacatca atctgtaggt gtaaaccaga 3600
attactcttt gtgaccacca ggaaatagag cagttcagtt caggggtttc tttctgtgaa 3660
tttagcactg tgacctgcat actacaagtc tactttgttt tctatccatt gtttgtatct 3720
gggtattgca aaaggtagga aaaggaccaa ccagatcagc agagaagagt tgccttggag 3780
ttttctttta gttttctgca gttcattaga tagtaactag gccatgtcat tttactccct 3840
tgtagtgaag atatgttgaa gttgtactgg tatactcttc tacctttctg taattttata 3900
ttgtgtagac ttgataaaat ttatgtgtca atcaccacca ttaatatcaa tattgagcct 3960
caattcttat ttttctgccc agtggctgcc aaattactaa catttacaat aattcactac 4020
tactaagata atctactagt tcgatcacat acttcaaatt gttatggaac tactgtcttc 4080
agcattgtgc ttctgataac tgataagtat aatttttttt ttgtccagag tgaacatgtc 4140
tattcttcca ctgtacacac taataaaagg aaaaattgta atattgggta aattcatgtc 4200
cttacacatg tagtagttat gagcccatgt ccctagaatg agtaataatt tatccctccc 4260
ttggttgaat agtcaagaat gctgatttta attcttctaa cagctttatc cctcagaagg 4320
gaaggcaagc aagttatata tgtagtttat ttgtaagact gatatgaaat tggaagatga 4380
atctactatt agctttaatt atttttacat ttaggaatat tgcatcagta actcataatt 4440
ttggttttct gttatcctga gttaacacaa attatccaag gagatggcgg atcatctgct 4500
ttgaggtgtt tttttttgag aattttaatg tatctgaata taaaaggtaa aaatatgcca 4560
actagcaatt tctgcccatt ccagaagttt ggaaatatta ctcattacta ggaattaaat 4620
aaaatatggt ttatctattg ttatacctct tttaattcac atagctcatt tttatctttt 4680
atttttgttt gttttttttg agatggagtc ttgctctgtc accaggcagg agtgcagtga 4740
tgcaatctcg gctcactcta gccaccgact ccctggttca agcgattctc ctgcctgagc 4800
cttctgagta gctgggatta caggcaggca ccaccacgcc cagctaattt ttgtagagac 4860
aggatttcac cgtgttggcc aggatggtct ccatctcctg acctcatgat ctgcctgctt 4920
cggcctccca aagtgctggg attacaggtg ggagccacta cgcctggccc acatagctca 4980
tttttagact cacttccatt aagtcttgtt tggacccacg aacattgtct tttttttttt 5040
aagatggagt ttcacttttg ttgcccagac tgtagtgcaa tggtgcaatc tcagctcact 5100
gcaatctctg cctcctgggt tctagcaatt ctcctgcctc agcctcccga gtagctggaa 5160
ttacaggcgc ccgccaccac gcccagctaa tttttgtgtt tttagtagag acggggtttc 5220
accatgttgg gcaggccagg ggtgatccgc ccacctcagc ctcccaaagt gctgggatta 5280
caggtgtgag ccaccgcatc tggccaacat gtcttttttt tttttttcct ttttaaccac 5340
aaagagactt aagcagtcct tgtcacagat gatgaattga tgttgcaagt attgtcttag 5400
cttggattaa ttttcttgct tactgtaatt ttagataata tagctttgta attagagatt 5460
ttatgtgtaa accacaaaaa tgtttacatg aaggccatta ttacagatgt gacgtgcata 5520
attattagta atttgtatgt ttacatgggt cagtctggca aaaaattatg aagttttaaa 5580
aattaaaaaa aattataatg ccagttttac tggaaagtaa aattatttca gtaatcgatt 5640
atagcaaaag tattgatttt cattccagac aaaagtcaga atgaaaggta atttctcaat 5700
actctttcag attaataaaa gtacctgtag cgatttttat cattcacaag tatatcacaa 5760
gtaagttaga atttgagaac tgtgttctag atctctgagg agatgcagtc agatttctga 5820
actgtctcag caaatggtaa gtaacttaga gctagtaatt aataacctgt cctttgattt 5880
ctgattcagc caagaatggc catatttggg aaaggcagat ctggagagta accacgtttt 5940
cattcattta ccacttctag gcccctccag agctctcaga tattttgggg ttgagccctt 6000
ccccaaagcc atacaggacc ttttttttgt gatctgttct agccattttt atgttgggtg 6060
cttgttatgg actgagcatt tatgtcctcc cacacccccc ccataccttt tttgaagtcc 6120
taacccccag tgtgatggta tttggagaca gggcctttgg aaggtaatta cagttagaag 6180
aagtcgggag ggttgggccc aggtctgatt ggattagtgc ccttatatga aaagacacca 6240
ggacgggcgc agtggctcac acctgtaatc ccagcacttt gggaggccaa ggtgggtgga 6300
tcacgaggtc aggagtttga gaccagcctg gccaatgtag tgaaacacca tctctactaa 6360
aaatacaaaa attagctggg tgtggtagcg ggctcctgtc atccaagcta ctcgggaggg 6420
tgaggcatga gaatcacttg aacccgggag ttggaggttg cagtgagccc agattgtgcc 6480
actgtactcc agcctgggtg acagagtgag actctgtctc aaaaaagaaa aaaaaaaaaa 6540
aagagacacc agagagcttg ttagaagagg tcatgtgagc acacagttag aagaccttca 6600
agccaaagaa gaggcctgag attgaaacct accttgcagg taccttaatt ttggacttcc 6660
cagcctccaa aactgtgaga aataagtttc tgttaagtca ctcagtctgt ggtattttgt 6720
tatggcagcc tgagcaggta gttgttcttt cagaaggtgt tgataataac cacatgcaac 6780
accaagtcac aaataataaa acagatgtaa cttatattca tacagaaagt tgggcactgc 6840
cattgccttg ttggtttaca cggctgtgct agttcagtag cagaaaggtg ctggtctcct 6900
ttactcagtt tacaatctag gcagtagaat gtaatcactg ctttaaactt gatactgctt 6960
agggagagaa tcattggtgc tgggtaacta cccagctttc ttgtacaaag tggttctacc 7020
gggtagggga ggcgcttttc ccaaggcagt ctggagcatg cgctttagca gccccgctgg 7080
gcacttggcg ctacacaagt ggcctctggc ctcgcacaca ttccacatcc accggtaggc 7140
gccaaccggc tccgttcttt ggtggcccct tcgcgccacc ttctactcct cccctagtca 7200
ggaagttccc ccccgccccg cagctcgcgt cgtgcaggac gtgacaaatg gaagtagcac 7260
gtctcactag tctcgtgcag atggacagca ccgctgagca atggaagcgg gtaggccttt 7320
ggggcagcgg ccaatagcag ctttgctcct tcgctttctg ggctcagagg ctgggaaggg 7380
gtgggtccgg gggcgggctc aggggcgggc tcaggggcgg ggcgggcgcc cgaaggtcct 7440
ccggaggccc ggcattctgc acgcttcaaa agcgcacgtc tgccgcgctg ttctcctctt 7500
cctcatctcc gggcctttcg acctcacgtg gccaccatga aaaagcctga actcaccgcg 7560
acgtctgtcg agaagtttct gatcgaaaag ttcgacagcg tctccgacct gatgcagctc 7620
tcggagggcg aagaatctcg tgctttcagc ttcgatgtag gagggcgtgg atatgtcctg 7680
cgggtaaata gctgcgccga tggtttctac aaagatcgtt atgtttatcg gcactttgca 7740
tcggccgcgc tcccgattcc ggaagtgctt gacattgggg aatttagcga gagcctgacc 7800
tattgcatct cccgccgtgc acagggtgtc acgttgcaag acctgcctga aaccgaactg 7860
cccgctgttc tgcagccggt cgcggaggcc atggatgcga tcgctgcggc cgatcttagc 7920
cagacgagcg ggttcggccc attcggaccg caaggaatcg gtcaatacac tacatggcgt 7980
gatttcatat gcgcgattgc tgatccccat gtgtatcact ggcaaactgt gatggacgac 8040
accgtcagtg cgtccgtcgc gcaggctctc gatgagctga tgctttgggc cgaggactgc 8100
cccgaagtcc ggcacctcgt gcacgcggat ttcggctcca acaatgtcct gacggacaat 8160
ggccgcataa cagcggtcat tgactggagc gaggcgatgt tcggggattc ccaatacgag 8220
gtcgccaaca tcttcttctg gaggccgtgg ttggcttgta tggagcagca gacgcgctac 8280
ttcgagcgga ggcatccgga gcttgcagga tcgccgcggc tccgggcgta tatgctccgc 8340
attggtcttg accaactcta tcagagcttg gttgacggca atttcgatga tgcagcttgg 8400
gcgcagggtc gatgcgacgc aatcgtccga tccggagccg ggactgtcgg gcgtacacaa 8460
atcgcccgca gaagcgcggc cgtctggacc gatggctgtg tagaagtact cgccgatagt 8520
ggaaaccgac gccccagcac tcgtccgagg gcaaaggaat agcagacatg ataagataca 8580
ttgatgagtt tggacaaacc acaactagaa tgcagtgaaa aaaatgcttt atttgtgaaa 8640
tttgtgatgc tattgcttta tttgtaacca ttataagctg caataaacaa gttaacaaca 8700
acaattgcat tcattttatg tttcaggttc agggggaggt gtgggaggtt ttttaaagca 8760
agtaaaacct ctacaaatgt ggtagtcgcc caca 8794
<210> 6
<211> 5320
<212> DNA
<213> Artificial sequence
<400> 6
cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgcccatt 60
gacgtcaata gtaacgccaa tagggacttt ccattgacgt caatgggtgg agtatttacg 120
gtaaactgcc cacttggcag tacatcaagt gtatcatatg ccaagtacgc cccctattga 180
cgtcaatgac ggtaaatggc ccgcctggca ttgtgcccag tacatgacct tatgggactt 240
tcctacttgg cagtacatct acgtattagt catcgctatt accatggtcg aggtgagccc 300
cacgttctgc ttcactctcc ccatctcccc cccctcccca cccccaattt tgtatttatt 360
tattttttaa ttattttgtg cagcgatggg ggcggggggg gggggggggc gcgcgccagg 420
cggggcgggg cggggcgagg ggcggggcgg ggcgaggcgg agaggtgcgg cggcagccaa 480
tcagagcggc gcgctccgaa agtttccttt tatggcgagg cggcggcggc ggcggcccta 540
taaaaagcga agcgcgcggc gggcgggagt cgctgcgcgc tgccttcgcc ccgtgccccg 600
ctccgccgcc gcctcgcgcc gcccgccccg gctctgactg accgcgttac tcccacaggt 660
gagcgggcgg gacggccctt ctcctccggg ctgtaattag ctgagcaaga ggtaagggtt 720
taagggatgg ttggttggtg gggtattaat gtttaattac ctggagcacc tgcctgaaat 780
cacttttttt caggttggac cggtgccacc atggactata aggaccacga cggagactac 840
aaggatcatg atattgatta caaagacgat gacgataaga tggccccaaa gaagaagcgg 900
aaggtcggta tccacggagt cccagcagcc gacaagaagt acagcatcgg cctggacatc 960
ggcaccaact ctgtgggctg ggccgtgatc accgacgagt acaaggtgcc cagcaagaaa 1020
ttcaaggtgc tgggcaacac cgaccggcac agcatcaaga agaacctgat cggagccctg 1080
ctgttcgaca gcggcgaaac agccgaggcc acccggctga agagaaccgc cagaagaaga 1140
tacaccagac ggaagaaccg gatctgctat ctgcaagaga tcttcagcaa cgagatggcc 1200
aaggtggacg acagcttctt ccacagactg gaagagtcct tcctggtgga agaggataag 1260
aagcacgagc ggcaccccat cttcggcaac atcgtggacg aggtggccta ccacgagaag 1320
taccccacca tctaccacct gagaaagaaa ctggtggaca gcaccgacaa ggccgacctg 1380
cggctgatct atctggccct ggcccacatg atcaagttcc ggggccactt cctgatcgag 1440
ggcgacctga accccgacaa cagcgacgtg gacaagctgt tcatccagct ggtgcagacc 1500
tacaaccagc tgttcgagga aaaccccatc aacgccagcg gcgtggacgc caaggccatc 1560
ctgtctgcca gactgagcaa gagcagacgg ctggaaaatc tgatcgccca gctgcccggc 1620
gagaagaaga atggcctgtt cggaaacctg attgccctga gcctgggcct gacccccaac 1680
ttcaagagca acttcgacct ggccgaggat gccaaactgc agctgagcaa ggacacctac 1740
gacgacgacc tggacaacct gctggcccag atcggcgacc agtacgccga cctgtttctg 1800
gccgccaaga acctgtccga cgccatcctg ctgagcgaca tcctgagagt gaacaccgag 1860
atcaccaagg cccccctgag cgcctctatg atcaagagat acgacgagca ccaccaggac 1920
ctgaccctgc tgaaagctct cgtgcggcag cagctgcctg agaagtacaa agagattttc 1980
ttcgaccaga gcaagaacgg ctacgccggc tacattgacg gcggagccag ccaggaagag 2040
ttctacaagt tcatcaagcc catcctggaa aagatggacg gcaccgagga actgctcgtg 2100
aagctgaaca gagaggacct gctgcggaag cagcggacct tcgacaacgg cagcatcccc 2160
caccagatcc acctgggaga gctgcacgcc attctgcggc ggcaggaaga tttttaccca 2220
ttcctgaagg acaaccggga aaagatcgag aagatcctga ccttccgcat cccctactac 2280
gtgggccctc tggccagggg aaacagcaga ttcgcctgga tgaccagaaa gagcgaggaa 2340
accatcaccc cctggaactt cgaggaagtg gtggacaagg gcgcttccgc ccagagcttc 2400
atcgagcgga tgaccaactt cgataagaac ctgcccaacg agaaggtgct gcccaagcac 2460
agcctgctgt acgagtactt caccgtgtat aacgagctga ccaaagtgaa atacgtgacc 2520
gagggaatga gaaagcccgc cttcctgagc ggcgagcaga aaaaggccat cgtggacctg 2580
ctgttcaaga ccaaccggaa agtgaccgtg aagcagctga aagaggacta cttcaagaaa 2640
atcgagtgct tcgactccgt ggaaatctcc ggcgtggaag atcggttcaa cgcctccctg 2700
ggcacatacc acgatctgct gaaaattatc aaggacaagg acttcctgga caatgaggaa 2760
aacgaggaca ttctggaaga tatcgtgctg accctgacac tgtttgagga cagagagatg 2820
atcgaggaac ggctgaaaac ctatgcccac ctgttcgacg acaaagtgat gaagcagctg 2880
aagcggcgga gatacaccgg ctggggcagg ctgagccgga agctgatcaa cggcatccgg 2940
gacaagcagt ccggcaagac aatcctggat ttcctgaagt ccgacggctt cgccaacaga 3000
aacttcatgc agctgatcca cgacgacagc ctgaccttta aagaggacat ccagaaagcc 3060
caggtgtccg gccagggcga tagcctgcac gagcacattg ccaatctggc cggcagcccc 3120
gccattaaga agggcatcct gcagacagtg aaggtggtgg acgagctcgt gaaagtgatg 3180
ggccggcaca agcccgagaa catcgtgatc gaaatggcca gagagaacca gaccacccag 3240
aagggacaga agaacagccg cgagagaatg aagcggatcg aagagggcat caaagagctg 3300
ggcagccaga tcctgaaaga acaccccgtg gaaaacaccc agctgcagaa cgagaagctg 3360
tacctgtact acctgcagaa tgggcgggat atgtacgtgg accaggaact ggacatcaac 3420
cggctgtccg actacgatgt ggaccatatc gtgcctcaga gctttctgaa ggacgactcc 3480
atcgacaaca aggtgctgac cagaagcgac aagaaccggg gcaagagcga caacgtgccc 3540
tccgaagagg tcgtgaagaa gatgaagaac tactggcggc agctgctgaa cgccaagctg 3600
attacccaga gaaagttcga caatctgacc aaggccgaga gaggcggcct gagcgaactg 3660
gataaggccg gcttcatcaa gagacagctg gtggaaaccc ggcagatcac aaagcacgtg 3720
gcacagatcc tggactcccg gatgaacact aagtacgacg agaatgacaa gctgatccgg 3780
gaagtgaaag tgatcaccct gaagtccaag ctggtgtccg atttccggaa ggatttccag 3840
ttttacaaag tgcgcgagat caacaactac caccacgccc acgacgccta cctgaacgcc 3900
gtcgtgggaa ccgccctgat caaaaagtac cctaagctgg aaagcgagtt cgtgtacggc 3960
gactacaagg tgtacgacgt gcggaagatg atcgccaaga gcgagcagga aatcggcaag 4020
gctaccgcca agtacttctt ctacagcaac atcatgaact ttttcaagac cgagattacc 4080
ctggccaacg gcgagatccg gaagcggcct ctgatcgaga caaacggcga aaccggggag 4140
atcgtgtggg ataagggccg ggattttgcc accgtgcgga aagtgctgag catgccccaa 4200
gtgaatatcg tgaaaaagac cgaggtgcag acaggcggct tcagcaaaga gtctatcctg 4260
cccaagagga acagcgataa gctgatcgcc agaaagaagg actgggaccc taagaagtac 4320
ggcggcttcg acagccccac cgtggcctat tctgtgctgg tggtggccaa agtggaaaag 4380
ggcaagtcca agaaactgaa gagtgtgaaa gagctgctgg ggatcaccat catggaaaga 4440
agcagcttcg agaagaatcc catcgacttt ctggaagcca agggctacaa agaagtgaaa 4500
aaggacctga tcatcaagct gcctaagtac tccctgttcg agctggaaaa cggccggaag 4560
agaatgctgg cctctgccgg cgaactgcag aagggaaacg aactggccct gccctccaaa 4620
tatgtgaact tcctgtacct ggccagccac tatgagaagc tgaagggctc ccccgaggat 4680
aatgagcaga aacagctgtt tgtggaacag cacaagcact acctggacga gatcatcgag 4740
cagatcagcg agttctccaa gagagtgatc ctggccgacg ctaatctgga caaagtgctg 4800
tccgcctaca acaagcaccg ggataagccc atcagagagc aggccgagaa tatcatccac 4860
ctgtttaccc tgaccaatct gggagcccct gccgccttca agtactttga caccaccatc 4920
gaccggaaga ggtacaccag caccaaagag gtgctggacg ccaccctgat ccaccagagc 4980
atcaccggcc tgtacgagac acggatcgac ctgtctcagc tgggaggcga caaaaggccg 5040
gcggccacga aaaaggccgg ccaggcaaaa aagaaaaagt aagaattcct agagctcgct 5100
gatcagcctc gactgtgcct tctagttgcc agccatctgt tgtttgcccc tcccccgtgc 5160
cttccttgac cctggaaggt gccactccca ctgtcctttc ctaataaaat gaggaaattg 5220
catcgcattg tctgagtagg tgtcattcta ttctgggggg tggggtgggg caggacagca 5280
agggggagga ttgggaagag aatagcaggc atgctgggga 5320
<210> 7
<211> 352
<212> DNA
<213> Artificial sequence
<400> 7
gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgttagagag 60
ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga 120
aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat 180
atgcttaccg taacttgaaa gtatttcgat ttcttggctt tatatatctt gtggaaagga 240
cgaaacaccg attgaggtac tgaaatgtgt gttttagagc tagaaatagc aagttaaaat 300
aaggctagtc cgttatcaac ttgaaaaagt ggcaccgagt cggtgctttt tt 352
<210> 8
<211> 26
<212> DNA
<213> Artificial sequence
<400> 8
gatctggaag gtgctgaggt acgatg 26
<210> 9
<211> 22
<212> DNA
<213> Artificial sequence
<400> 9
aagggtcgtc cgcaggattc ag 22
<210> 10
<211> 21
<212> DNA
<213> Artificial sequence
<400> 10
cactcgtccg agggcaaagg a 21
<210> 11
<211> 24
<212> DNA
<213> Artificial sequence
<400> 11
gcttccatca aacgagttgg tgct 24
<210> 12
<211> 24
<212> DNA
<213> Artificial sequence
<400> 12
caagacctgc ctgaaaccga actg 24
<210> 13
<211> 24
<212> DNA
<213> Artificial sequence
<400> 13
aagcatcagc tcatcgagag cctg 24

Claims (9)

1. A cell obtained by inserting an exogenous fragment comprising LoxM2, HPRT intron and Hygro cassette into the genome of 293A cells at the position of Ad5 gene.
2. The cell according to claim 1, wherein the nucleotide sequence of LoxM2 is shown in SEQ ID No.1, the nucleotide sequence of HPRT intron is shown in SEQ ID No.2, and the nucleotide sequence of Hygro cassette is shown in SEQ ID No. 3.
3. The cell of claim 2, wherein the exogenous fragment has the nucleotide sequence set forth in SEQ ID No. 5.
4. The cell of claim 1, wherein the insertion is at a position 3522bp of the Ad5 gene.
5. The method for constructing the cell according to any one of claims 1 to 4, wherein the method comprises inserting an exogenous fragment comprising LoxM2, HPRT intron and Hygro cassette at the position of Ad5 gene in 293A cell genome.
6. The construction method according to claim 5, wherein the construction method is to use a non-homology-dependent targeted integration method to make the genome of 293A cell and the plasmid carrying the exogenous fragment form DNA double-strand break by using CRISPR/Cas9 system, and insert the linearized exogenous fragment into the targeted site of the cell genome by using a non-homology end-linked DNA repair pathway, so as to form targeted integration.
7. The method of claim 6, wherein the plasmid carrying the exogenous fragment is pDOwn-HBV ployA-HPRT intron-mPGK-Hygro-SV40 pA-gRNA 2.
8. A method of packaging an adenovirus using a cell according to any one of claims 1 to 4, wherein said method comprises infecting said cell with an adenovirus lacking the E1 gene.
9. Use of a cell according to any one of claims 1 to 4 in the preparation of an adenovirus.
CN202111116064.4A 2021-09-23 2021-09-23 293A cell strain for producing adenovirus and preparation and application thereof Active CN113755447B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111116064.4A CN113755447B (en) 2021-09-23 2021-09-23 293A cell strain for producing adenovirus and preparation and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111116064.4A CN113755447B (en) 2021-09-23 2021-09-23 293A cell strain for producing adenovirus and preparation and application thereof

Publications (2)

Publication Number Publication Date
CN113755447A true CN113755447A (en) 2021-12-07
CN113755447B CN113755447B (en) 2022-04-29

Family

ID=78797070

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111116064.4A Active CN113755447B (en) 2021-09-23 2021-09-23 293A cell strain for producing adenovirus and preparation and application thereof

Country Status (1)

Country Link
CN (1) CN113755447B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107109434A (en) * 2014-10-23 2017-08-29 瑞泽恩制药公司 Novel CHO integration sites and its purposes
CN111088251A (en) * 2019-12-26 2020-05-01 云舟生物科技(广州)有限公司 Gene expression cassette and application thereof in Cre-lox recombination efficiency detection
WO2021003432A1 (en) * 2019-07-02 2021-01-07 Fred Hutchinson Cancer Research Center Recombinant ad35 vectors and related gene therapy improvements

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107109434A (en) * 2014-10-23 2017-08-29 瑞泽恩制药公司 Novel CHO integration sites and its purposes
WO2021003432A1 (en) * 2019-07-02 2021-01-07 Fred Hutchinson Cancer Research Center Recombinant ad35 vectors and related gene therapy improvements
CN111088251A (en) * 2019-12-26 2020-05-01 云舟生物科技(广州)有限公司 Gene expression cassette and application thereof in Cre-lox recombination efficiency detection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A ALLARD 等: "The E1B transcription map of the enteric adenovirus type 41", 《VIROLOGY》 *
ZHIBIN WANG 等: "Characterization of integration frequency and insertion sites of adenovirus DNA into mouse liver genomic DNA following intravenous injection", 《GENE THERAPY》 *

Also Published As

Publication number Publication date
CN113755447B (en) 2022-04-29

Similar Documents

Publication Publication Date Title
US8398968B2 (en) Adenoviral expression vectors
US5891690A (en) Adenovirus E1-complementing cell lines
AU756629B2 (en) Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods
US8586024B2 (en) Long lasting drug formulations
CN113302201A (en) Recombinant viral vectors and nucleic acids for producing the same
CN1113390A (en) Defective adenovirus vectors and use thereof in gene therapy
EP0988391B1 (en) Recombinant adenoviral vectors comprising a splicing sequence
EP3670650B1 (en) Cell strain for reducing production of reproducible adenovirus, and construction method and use
JP2000106875A (en) Use of adenovirus e4 leading frme for improving expression of target gene
US6806080B2 (en) Hybrid vectors for gene therapy
KR20230118075A (en) Compositions and methods for the treatment of Fabry disease
US7563617B2 (en) Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
US20040191222A1 (en) Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby
CN113755447B (en) 293A cell strain for producing adenovirus and preparation and application thereof
ES2239841T3 (en) CHEMICAL ADENOVIRAL VECTORS.
US6489142B1 (en) Methods and compositions for producing viral particles
WO1997015679A9 (en) Recombinant viruses containing mobile genetic elements and methods of use in gene therapy
CN112961840B (en) Recombinant oncolytic virus and preparation method and application thereof
KR20220145838A (en) Compositions useful for treating GM1 gangliosiosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Room d301-d309, Guangzhou International Business Incubator (Zone D), No.3, Juquan Road, Science City, Guangzhou hi tech Industrial Development Zone, Guangzhou, Guangdong 510663

Applicant after: Yunzhou Biotechnology (Guangzhou) Co.,Ltd.

Address before: Room d301-d309, Guangzhou International Business Incubator (Zone D), No.3, Juquan Road, Science City, Guangzhou hi tech Industrial Development Zone, Guangzhou, Guangdong 510663

Applicant before: YUNZHOU BIOSCIENCES (GUANGZHOU) Inc.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: A 293A cell line for adenovirus production and its preparation and application

Effective date of registration: 20230717

Granted publication date: 20220429

Pledgee: China Merchants Bank Limited by Share Ltd. Guangzhou branch

Pledgor: Yunzhou Biotechnology (Guangzhou) Co.,Ltd.

Registration number: Y2023440000069

PE01 Entry into force of the registration of the contract for pledge of patent right